Post-earnings recap
Reported
Tue, Feb 19, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Ultragenyx's earnings report showed a miss on EPS, which typically raises concerns among investors. However, the stock reacted positively, increasing by 0.28%. This could indicate that investors are focusing more on the company's long-term potential and recent positive developments in their clinical trials rather than the immediate EPS result.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.73 | N/A | -5.88% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious optimism about the future, emphasizing their commitment to advancing their drug pipeline. They acknowledged the EPS miss but pointed to positive developments in clinical trials as a bright spot.
Management highlighted ongoing commitment to pipeline development.
They noted positive feedback from recent clinical trials.
Focus remains on long-term growth despite current EPS miss.